Bryan J. McMichael
Known title: See RemarksCIK: 0001944868
Associated companies
Transaction History
| CHRS | ▲ Buy | Grant | 112,500 | $0 | 1/22/2026 | View on chart |
| CHRS | ▼ Sell | Tax Withholding | 1,715 | $3K | 1/20/2026 | View on chart |
| CHRS | ▼ Sell | Tax Withholding | 1,711 | $2K | 1/20/2025 | View on chart |
| CHRS | ▼ Sell | Tax Withholding | 1,711 | $3K | 1/7/2025 | View on chart |
| CHRS | ▼ Sell | Tax Withholding | 1,707 | $4K | 1/20/2024 | View on chart |
| CHRS | ▼ Sell | Tax Withholding | 1,707 | $5K | 1/7/2024 | View on chart |
| CHRS | ▲ Buy | Grant | 12,500 | $0 | 1/20/2023 | View on chart |
| CHRS | ▼ Sell | Tax Withholding | 1,699 | $16K | 1/7/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
CHRS Retains Oppenheimer to Market Legacy Biosimilar Assets
Coherus Oncology announced that it has retained Oppenheimer & Co. to market its legacy biosimilar assets. The move aims to increase visibility and potential partnerships for older products in its pipeline. The stock is currently near a long‑standing support level, which may draw attention as the company pursues these marketing efforts.
CHRS Retains Oppenheimer to Market Legacy Biosimilar Assets. Coherus Oncology announced that it has retained Oppenheimer & Co. to market its legacy biosimilar assets. The move aims to increase visibility and potential partnerships for older products in its pipeline. The stock is currently near a long‑standing support level, which may draw attention as the company pursues these marketing efforts.